Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Gilteritinib (Primary) ; Ziftomenib (Primary) ; Azacitidine; Cytarabine; Daunorubicin; Fludarabine; Granulocyte colony-stimulating factors; Idarubicin; Venetoclax
Indications Acute myeloid leukaemia
Focus Adverse reactions
Acronyms KOMET-008
Sponsors Kura Oncology

26 Feb 2024 According to Kura Oncology media release, today company announced that the first patient has been dosed in KOMET-008.
10 Jan 2024 Planned initiation date changed from 1 Dec 2023 to 1 Jan 2024.
13 Dec 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com